VOLITIONRX LTD
VNRXNYSE
$1.10
↓ -5.2%Jul 17 close · end-of-day
Price
1Y↓ -92.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.6M
Enterprise Value
$14.9M
P/E
—
P/S
3.1
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-274.2%
Dividend Yield
—
Revenue (TTM)
$2.5M
Net Income (TTM)
-$24.6M
Free Cash Flow (TTM)
-$20.8M
Gross Margin
—
Operating Margin
-874.5%
Net Margin
-997.5%
ROE
76.9%
ROIC
—
Debt / Equity
-0.2
Net Cash
-$7.3M
Return 1Y
-91.9%
Company profile
VolitionRx Limited engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; NuQ Nets, monitoring the immune system, and NuQ Vet cancer screening test for veterinary applications. The company operates Nucleosomics a technology platform.
- CEO
- Cameron J. Reynolds
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Nevada
- Website
- volition.com
Earnings
VNRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$985,076.00↑ +299.8%
Diluted EPS-$0.97↓ -13.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13,433.00 | $90,035.00 | $306,392.00 | $775,302.00 | $1.2M | $1.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$21.2M | -$28.3M | -$31.8M | -$36.0M | -$27.0M | -$21.7M |
| Net income | -$20.4M | -$27.0M | -$30.6M | -$35.7M | -$27.0M | -$23.4M |
| Diluted EPS | — | — | — | -$0.50 | -$0.31 | — |
| Operating cash flow | -$16.5M | -$20.9M | -$15.3M | -$18.1M | -$25.9M | -$19.7M |
| Free cash flow | -$18.4M | -$21.8M | -$16.8M | -$19.1M | -$26.2M | -$19.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -158176.2% | -31469.0% | -10372.4% | -4641.8% | -2190.9% | -1258.5% |
| Net margin | -151859.6% | -29977.0% | -9986.7% | -4601.7% | -2186.3% | -1352.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $395,797.00 | $474,522.00 | $191,657.00 | $246,385.00 | $406,688.00 | $627,277.00 | $447,034.00 | $985,076.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.0M | -$5.9M | -$5.8M | -$5.5M | -$6.3M | -$5.1M | -$4.8M | -$5.3M |
| Net income | -$7.0M | -$5.8M | -$5.8M | -$5.4M | -$6.3M | -$5.4M | -$6.3M | -$6.7M |
| Diluted EPS | -$0.08 | -$0.07 | -$0.06 | -$1.12 | -$0.06 | -$0.05 | — | -$0.97 |
| Operating cash flow | -$6.7M | -$5.4M | -$5.4M | -$4.3M | -$6.3M | -$3.6M | -$5.5M | -$5.3M |
| Free cash flow | -$6.8M | -$5.5M | -$5.5M | -$4.3M | -$6.3M | -$3.6M | -$5.5M | -$5.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1766.2% | -1236.8% | -3016.5% | -2241.1% | -1548.6% | -813.2% | -1077.8% | -543.0% |
| Net margin | -1764.9% | -1226.8% | -3022.8% | -2201.3% | -1545.2% | -857.4% | -1402.8% | -676.6% |
Company news
Jul 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.